Optimal patient selection for anticoagulant therapy in sepsis: an evidence-based proposal from Japan

Journal of Thrombosis and Haemostasis

Volumn 16, Issue 3, 2018, Pages 462-464

  Umemura, Y ^a,b   Yamakawa, K ^a  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

anticoagulants; disseminated intravascular coagulation; review; sepsis; severity of illness

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; RECOMBINANT PROTEIN; THROMBOMODULIN;

BLEEDING; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; JAPAN; LETTER; MORTALITY RATE; MORTALITY RISK; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEPSIS; SURVIVAL ANALYSIS; COMPLICATION; EPIDEMIOLOGY; META ANALYSIS; MORTALITY; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; RISK;

ANTICOAGULANTS; ANTITHROMBINS; DISSEMINATED INTRAVASCULAR COAGULATION; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HUMANS; JAPAN; MULTICENTER STUDIES AS TOPIC; OBSERVATIONAL STUDIES AS TOPIC; PATIENT SELECTION; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK; SEPSIS; THROMBOMODULIN;

EID: 85041119048     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13946     Document Type: Letter

References (13)

1. Allingstrup M, Wetterslev J, Ravn FB, Møller AM, Afshari A. Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 2016; 42: 505–20.
2. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med 2017; 43: 304–77.
3. van der Poll T, Opal SM. Should all septic patients be given systemic anticoagulation? No Intensive Care Med 2017; 43: 455–7.
4. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke HO, Warren BL, Opal SM;KyberSept Investigators. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006; 34: 285–92.
5. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM;KyberSept investigators. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006; 4: 90–7.
6. Umemura Y, Yamakawa K, Ogura H, Yuhara H, Fujimi S. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials. J Thromb Haemost 2016; 14: 518–30.
7. Yamakawa K, Umemura Y, Hayakawa M, Kudo D, Sanui M, Takahashi H, Yoshikawa Y, Hamasaki T, Fujimi S. Japan septic disseminated intravascular coagulation (J-Septic DIC) study group. Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan. Crit Care 2016; 20: 229.
8. Wiedermann CJ. Antithrombin concentrate use in disseminated intravascular coagulation of sepsis: Meta-analyses revisited. J Thromb Haemost 2018. [Epub ahead of print]
9. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013; 13: 34–45.
10. Gando S, Saitoh D, Ishikura H, Ueyama M, Otomo Y, Oda S, Kushimoto S, Tanjoh K, Mayumi T, Ikeda T, Iba T, Eguchi Y, Okamoto K, Ogura H, Koseki K, Sakamoto Y, Takayama Y, Shirai K, Takasu O, Inoue Y, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care 2013; 17: R297.
11. Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, Hoste E, Levy H, Hirman J, Levi M, Daga M, Kutsogiannis DJ, Crowther M, Bernard GR, Devriendt J, Puigserver JV, Blanzaco DU, Esmon CT, Parrillo JE, Guzzi L, et al. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 2013; 41: 2069–79.
12. Yoshimura J, Yamakawa K, Ogura H, Umemura Y, Takahashi H, Morikawa M, Inoue Y, Fujimi S, Tanaka H, Hamasaki T, Shimazu T. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Crit Care 2015; 19: 78.
13. Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki T, Shimazu T. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost 2015; 13: 508–19.